Lycopene and Cardiovascular Disease

8/14/2019 Lycopene and Cardiovascular Disease

1/34

Lycopene and Cardiovascular

Disease

Presented by :

Anjali Tiwari


2/34

Introduction

1. Lycopene and CVD disease ,

2. Plasma lycopene ,other caoteniods ,and

retinol and the risk of CVD in men .3. Plasma lycopene ,other caoteniods ,and

retinol and the risk of CVD in women .


3/34

What is lycopene ?

Lycopene is hydrocarbon carotenoidwhich has received attention for itspotential role in preventing prostate cancer

and CVD disease in humans . In 1989 Di Mascio et al showed that

lycopene has strongest oxygen quenching

capacity of several carotenoids , withalpha carotene ,beta carotene ,andlutein next in capacity.


4/34

In study 1st it include

Introduction

Food sources and absorption of lycopene

Lycopene and smoking Biological activity of lycopene

Epidemiologic Evidence


5/34


6/34


7/34


8/34


9/34

Study 2nd & 3rd include

Subject and methods

Result

Discussion


10/34

In subjects and method of 2nd &3rd

study include Study population :-

The WHS is ongoingrandomized ,double blind ,placebo controlled

2x2 factorial trial of the relationship between low- dose aspirin vitamin E and primary preventionof CVD & cancer.

39,876 female US health professionals aged >

45 y in 1992 ,were postmenopausal or notintending to became pregnant , and had nohistory of MI , stroke ,transient ischemic attackor cancer were enrolled in study.


11/34

Subject & method of 2nd & 3rd

study.

Fasting baseline blood samples were

collected from 28,345 (71%) participants

and stored in liquid nitrogen until

analyzed .


12/34


study. Study population of 3rd study :

The PHS began as trialin 1982 of 22,071 men testing aspirin and beta carotenein the primary prevention f cancer and CVD ,it was

completed in 1995.PHS 2 was initiated as randomized ,double blind ,placebo- controlled ,2x2x2x2 factorial trial testing thebenefits and risk of vitamin E ,VIT C a multivitamin ,and beta carotene in the primary prevention of cancer,CVD and other chornic disease in male physicians aged>50 y ,including 7641 original physicians from the PHSplus 7000 new Physicians were recruited. fasting bloodsamples were collected from PHS in 1996


13/34


study.

Blood assays :-

Baseline blood samples from

cases & control were thawed and assayed for

total lycopene ,other carotenoids and retinol atOur lady of Mercy Medical centre Bronx (NY).

All assays was quantified by conventional

method .Plasma lipid including total cholesterol

and HDL cholesterol , using commerciallyavailable diagnostic kits (sigma aldrich

chemical Co , St louis , Mo) .


14/34


study.

Blood Assays..

Plasma total cholesterol was assayed

because plasma lipoprotein are non

specific carrier for all the caroteniods in

plasma &to date ,total cholesterol

appears to be best way to control for

confounding effects due to differences inlipoprotein concentration between subjects

.


15/34


study. Baseline covariates :-

Women from WHS and Menfrom PHS provided self reported dad on age (in ),weight & height (converted to body mass index ; in kg

/m2 ), smoking status (categorized as never , former , orcurrent ), alcohol use (categorized as rarely or never,


16/34


study. Data analyses:

Men from PHS & women fromWHS were first compared to case control status

by using mean value or proportion of baselinecoronary disease risk factors and biochemicalmakers .

Measurements of plasma lycopene

concentration were divided into quartiles basedon overall distribution of plasma lycopeneamong the 499 for men in controls &483 forwomen in controls.


17/34

Results of 2nd study


18/34


19/34


20/34


21/34


22/34


23/34


24/34


25/34


26/34


27/34


28/34


29/34


30/34


31/34


32/34


33/34


34/34

Lycopene and Cardiovascular Disease

Documents

Transcript of Lycopene and Cardiovascular Disease